Journal
FRONTIERS IN IMMUNOLOGY
Volume 12, Issue -, Pages -Publisher
FRONTIERS MEDIA SA
DOI: 10.3389/fimmu.2021.725204
Keywords
tumour dormancy; immunosuppression; kynurenine; nanotechnology; IDO1 regulation; aryl hydrocarbon receptor
Categories
Funding
- Natural Science Foundation of Jiangsu Province, China [BK20190960]
- Natural Science Foundation of the Jiangsu Higher Education Institutions of China [19KJB180014]
- China Postdoctoral Science Foundation [2019M663456, 2019TQ0044]
- Xinglin Scholar Research Promotion Project of Chengdu University of TCM [BSH2019008]
- Sichuan Province Science and technology innovation seedling project [2020091]
- Open Research Fund of Chengdu University of Traditional Chinese Medicine Key Laboratory of Systematic Research of Distinctive Chinese Medicine Resources in Southwest China [2020BSH004]
- Canada Mitacs Fellowship [IT18262]
Ask authors/readers for more resources
This review highlights the connection between IDO1 and tumour dormancy, emphasizing the importance of understanding IDO1 pathways in cancer development and progression. The involvement of distinct IDO1 activities in dormancy initiation and maintenance, as well as the potential role of other factors outside the well-studied IDO1/kynurenine/aryl hydrocarbon receptor axis, are discussed. Various strategies for cancer treatment via regulating IDO1-dependent dormancy and the potential application of nanotechnology for effective treatment delivery are also proposed.
The connection between indoleamine 2,3-dioxygenase 1 (IDO1) and tumour dormancy - a quiescent state of tumour cells which has been consistently linked to metastasis and cancer recurrence - is rarely discussed despite the pivotal role of IDO1 in cancer development and progression. Whilst the underlying mechanisms of IDO1-mediated dormancy are elusive, we summarize the IDO1 pathways which potentially contribute to dormancy in this review. Critically, distinct IDO1 activities are involved in dormancy initiation and maintenance; factors outside the well-studied IDO1/kynurenine/aryl hydrocarbon receptor axis, including the mammalian target of rapamycin and general control nonderepressible 2, appear to be implicated in dormancy. We also discuss various strategies for cancer treatment via regulating IDO1-dependent dormancy and suggest the application of nanotechnology to deliver effective treatment.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available